For a patient with metastatic urothelial cancer who has progressed on platinum-based chemotherapy, do you test for tumor PD-L1 expression prior to choosing atezolizumab as second-line treatment?
In the IMvigor 210 trial, increased PD-L1 expression in patients’ tumors was associated with response to atezolizumab, but some patients whose tumors were negative for PD-L1 still responded. Do you switch all patients to atezolizumab after progression on platinum, or only those with PD-L1 expression?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Icahn School of Medicine at Mount Sinai
Answered on
Currently, atezolizumab is the only drug FDA approved for treatment of patients with metastsatic urothelial cancer progressive despite first-line platinum based chemotherapy. Prior to the approval of atezolizumab, commonly used agents were taxanes or pemetrexed based on small to moderate sized singl...
Join for free or sign in to see the full answer